Alterations of p53 and Bcl-2 protein expression in the recurrent laryngeal and pharyngeal squamous cell carcinoma

Rashad, U M; Hussein, Mahmoud R.; Algizawy, Samy M

doi:10.1016/j.amjoto.2010.01.012

Cited by 9 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Bcl-2 gene is an antiapoptotic-membrane-associated molecule that resides in the nuclear envelope and mitochondria. It exerts its antiapoptotic functions by modulating the mitochondrial release of cytochrome c and the interaction of apoptosis activating factors (Apaf-1) with caspase 9, Bax and c-Myc (23).…”

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Bcl-2 Expression in Squamous Cell Carcinoma of the Larynx: A Systematic Review

Gioacchini

Alicandri‐Ciufelli

Rubini³

et al. 2015

Int J Biol Markers

View full text Add to dashboard Cite

The aim of this systematic review was to determine the prognostic value of Bcl-2 immunostaining in patients affected by laryngeal squamous cell carcinoma. An appropriate search was conducted on PubMed to retrieve articles dealing with this topic. A double cross-check was performed on citations and full-text articles by 2 investigators independently to review all manuscripts and perform a comprehensive quality assessment. Of 115 abstracts identified, 15 articles were included. These studies reported on 1,150 patients with histologically confirmed diagnosis of laryngeal squamous cell carcinoma. Only a few studies showed a statistical correlation between Bcl-2 immunohistochemical expression and at least 1 of the clinical and histopathological parameters considered by the authors. Moreover, these findings were also discordant between them. Overall the studies analyzed suggested that Bcl-2 expression was statistically connected with N stage (2/14), grading (2/14), disease-free survival (3/14) and overall survival (5/14). Interestingly, all of the 3 studies investigating the relation between Bcl-2 and radioresistance showed significant results in terms of recurrence-free survival and overall survival. Our review strongly suggests that the immunohistochemical staining of Bcl-2 does not correlate with tumoral aggressiveness and prognosis of patients affected by laryngeal squamous cell carcinoma and treated with primary surgery. However, an interesting connection of this protein could be demonstrated with tumoral radioresistance. Further, high-quality prospective studies should be carried out to confirm this hypothesis.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Bcl-2 Expression in Squamous Cell Carcinoma of the Larynx: A Systematic Review

Gioacchini

Alicandri‐Ciufelli

Rubini³

et al. 2015

Int J Biol Markers

View full text Add to dashboard Cite

show abstract

“…Immunohistochemically, both AFX and squamous cell carcinomas are positive for broad-spectrum cytokeratin antibodies, albeit being focal in the former [98,99]. At the molecular level, both AFX and squamous cell carcinoma show alterations of p53, other pro-apoptotic and anti-apoptotic molecules [60,70,100,101].…”

Section: A Speculative View About Afx and Epithelial-mesenchymal Transimentioning

confidence: 99%

Atypical fibroxanthoma: new insights

Hussein

2014

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Atypical fibroxanthoma (AFX) is an ultraviolet radiation-associated dermal neoplasm. To address the clinicopathologic and molecular features of this particular neoplasm. The author conducted a literature review using PubMed searching for articles relating to AFX. AFX usually appears as a rapidly growing nodular or nodulo-ulcerative lesion. It occurs on sun-exposed skin of elderly peoples. AFX may be composed predominantly of pleomorphic, spindle, epithelioid cells, or admixture of these cells. The differential diagnosis of AFX includes pleomorphic dermal sarcoma, squamous cell carcinoma, malignant melanoma and leiomyosarcoma. Several observations favor a mesenchymal origin for AFX. These reviews address the clinicopathologic features, molecular pathology, prognosis and treatment of this neoplasm.

show abstract

“…Positive and negative controls: Sections with phosphate buffer solution replacing the primary antibody were used as negative controls (Rashad et al, 2011). Positive controls included mesothelioma tissue for HBME-1 (Riera et al, 1997), Ureteric tissue for CK19 (Kasper et al, 1987), papillary thyroid carcinoma for Galectin-3 (Konstantinov et al, 1996), and Small cell lung carcinoma for CD56 antibodies (Tsang et al, 1996).…”

Section: Resultsmentioning

confidence: 99%

Challenge in the Pathological Diagnosis of the Follicular- Patterned Thyroid Lesions

Elsers

Hussein

Osman

et al. 2021

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Background: The follicular-patterned thyroid lesions (FPTLs) include hyperplastic nodules (HN), follicular adenoma (FA), non-invasive follicular neoplasm with papillary-like nuclear features (NIFTP), follicular carcinoma (FC), and the follicular variant of papillary carcinoma (FVPTC). Sometimes the pathologists cannot accurately separate these lesions from each others on a histological basis. Aims: To evaluate the utility of immunohistochemistry in the diagnosis of FPTLs. Materials and methods: Immunohistochemical analysis, incorporating 83 cases of histologically confirmed FPTLs out of which 20 carcinomas, 51 benign FPTLs (38 HN and 13 FA), and 12NIFTP were separated from each others using four immunostains (HBME-1, CK19, Galectin-3, and CD56). Results: We found statistically significantly more frequent expression of HBME-1, CK19, Galectin-3 proteins in carcinomas as compared to benign FPTLs (p = <0.01). HBME-1 and Galectin-3 were the most sensitive markers for the diagnosis of malignant FPTLs (75%). Galectin-3 was the most specific marker for the diagnosis of carcinoma (90.3%). Conclusions: The histomorphological features remain the cornerstone of the diagnosis of FPTN. Although HBME-1, Galectin-3, and CK19 immunostains have some diagnostic value in the separation of malignant from benign FPTLs, they are variably expressed in the benign and malignant FPTLs. No single immunostain has sufficient sensitivity and specificity and therefore their diagnostic use is controversial. Future studies are mandated to find more reliable markers that can separate between benign and malignant FPTLs.

show abstract

Alterations of p53 and Bcl-2 protein expression in the recurrent laryngeal and pharyngeal squamous cell carcinoma

Cited by 9 publications

References 9 publications

Prognostic Value of Bcl-2 Expression in Squamous Cell Carcinoma of the Larynx: A Systematic Review

Prognostic Value of Bcl-2 Expression in Squamous Cell Carcinoma of the Larynx: A Systematic Review

Atypical fibroxanthoma: new insights

Challenge in the Pathological Diagnosis of the Follicular- Patterned Thyroid Lesions

Contact Info

Product

Resources

About